HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Walgreens Boots Alliance Inc. (NASDAQ: WBA) is set to go private after nearly a century as a publicly traded company. Private equity firm Sycamore Partners has agreed to acquire Walgreens in a leveraged buyout worth up to $23.7 billion, including debt and potential future payouts.
Under the deal, Sycamore will pay $11.45 per share in cash, with Walgreens shareholders eligible for up to an additional $3 per share based on the sale of the company’s primary-care assets. Factoring in assumed debt, the transaction could reach a total valuation of $24 billion.
Walgreens CEO Tim Wentworth emphasized that while the company has made progress on its turnaround strategy, transitioning to a private entity will allow for more efficient restructuring. He highlighted Sycamore’s expertise in retail turnarounds as a key advantage for the company’s future growth.
The acquisition follows Walgreens' struggles in the competitive pharmacy and retail healthcare industry. By going private, Walgreens aims to streamline operations and navigate market challenges without the pressures of public trading.
The deal includes a 35-day “go-shop” period, allowing Walgreens to seek alternative offers. Pending regulatory approvals, the acquisition is expected to close in the fourth quarter of this year. Investors will closely monitor the transaction, marking one of the largest leveraged buyouts in recent years.
